Does Cangrelor reduce death, ischemic, and bleeding events in patients with acute coronary syndrome undergoing percutaneous coronary intervention?
In a real-world registry of ACS patients undergoing PCI, cangrelor use was associated with a significant reduction in in-hospital definite stent thrombosis.
-I. Clinical endpoints included death, ischemic and bleeding events occurring during hospital stay. Cangrelor treated patients presented higher clinical risk profile at presentation and faced higher death rate. However, after PS matching, in-hospital mortality resulted comparable between the groups and Cangrelor use was associated with reduced in-hospital definite stent thrombosis (p = 0.03). Data from our real-world registry highlight that, in the setting of ACS, Cangrelor is prevalently used in patients with very challenging clinical presentations. The adjusted analysis provides for the first time promising data on stent thrombosis reduction associated with Cangrelor use.
Pepe et al. (Sat,) studied this question.